ANTIDEPRESSANT MEDICATION & RISK OF DEMENTIA
|
|
- Gertrude Doyle
- 6 years ago
- Views:
Transcription
1 ANTIDEPRESSANT MEDICATION & RISK OF DEMENTIA A Nationwide Cohort Study in Taiwan / Speaker: Chee-Kin Then / Advisor: Prof. Shing-Chuan Shen / Unit: Graduate Institute of Medical Sciences / Date:
2 Dementia A clinical syndrome characterized by cognitive impairment, which including difficulties in thinking, memory, language and emotion 02
3 Mixed dementia Alzheimer s disease Vascular dementia Dementia with Lewy bodies Frontotemporal dementia 03
4 In Taiwan, the age-adjusted prevalence of all-cause dementia, was 8.04% Sun Y. et al. A Nationwide Survey of Mild Cognitive Impairment and Dementia, Including Very Mild Dementia, in Taiwan. PloS one. Jun ;9(6) 04
5 Younger onset depression is a risk factor of late life dementia They are comorbidity, share common risk factors or similar pattern of neuronal injury Depression can act as symptom or consequence of dementia Bennett S, Thomas AJ. Depression and dementia: cause, consequence or coincidence? Maturitas. Oct 2014;79(2):
6 1 Study by using Taiwan s NHIRD illustrated populations with dementia have higher ratio in taking antidepressants 2 Causes severe neurological side effects, which reflects antidepressants would interfere neurotransmitter systems 3 Cytotoxicity, damage normal cells which include osteoblasts, osteoclasts, hepatocytes, etc Madhusoodanan S, et al. Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. Aug 2010;22(3): Hodge JM, et al. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biological psychiatry. Jul ;74(1): Hsiao FY, et al. Dose-responsive effect of psychotropic drug use and subsequent dementia: a nationwide propensity score matched case-control study in Taiwan. Journal of the American Medical Directors Association. Jul 2014;15(7):
7 Antidepressant medication would increase the risk of dementia TCAs & TeCAs SSRIs SARIs MAOIs SNRIs 07
8 In Taiwan, the prevalence of antidepressants use 3.21% 4.63% Year 2000 Year 2009 Wu CS, Shau WY, Chan HY, Lee YC, Lai YJ, Lai MS. Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to Pharmacoepidemiology and drug safety. Sep 2012;21(9):
9 Study Design 9 years 4 years Outcome: Dementia years Antidepressant(+/-) Risk factors: Stroke Depression Diabetes Mellitus Hypertension Hyperlipidemia With 1:4 age-, sex- and date-matched schema: 5819 cases and controls were enrolled 09
10 Table 1. Comparison of demographic characteristics and risk factors between cases and controls Study (n=5,819) Control (n=23,276) P value n (%) n (%) Age group (years) * ,510 (25.95%) 6,051 (26.00%) ,606 (44.78%) 10,407 (44.71%) 65 1,703 (29.27%) 6,818 (29.29%) Sex (male) * 2,508 (43.10%) 10,032 (43.10%) 0 Insurance amount (NT$) * < , (14.14%) 2,955 (17.18%) 20,000-39, (21.64%) 4,580 (26.62%) <20,000 2,712 (64.22%) 9,670 (56.20%) Region *.003 North 2,565 (44.31%) 10,312 (44.51%) Center 1,414 (24.43%) 5,740 (24.77%) South 1,639 (28.31%) 6,622 (28.58%) East 171 (2.95%) 495 (2.14%) Urbanicity * < (most urbanized) 1,744 (33.23%) 7,439 (35.12%) 2 1,748 (33.31%) 6,672 (31.50%) (15.68%) 3,621 (17.09%) 4(least urbanized) 933 (17.78%) 3,450 (16.29%) Risk factors * Stroke 357 (6.14%) 610 (2.62%) <.001 Depression 969 (16.65%) 434 (1.86%) <.001 Diabetes Mellitus 721 (12.39%) 2,103 (9.04%) <.001 Hypertension 1,128 (19.38%) 3,903 (16.77%) <.001 Hyperlipidemia 775 (13.32%) 2,514 (10.80%) <.001 *Chi-square test. Subjects for all levels do not sum up to original cases due to missing values. Note: NT = New Taiwan. 10
11 Table 2 Logistic regressions of factors associated with the treated incidence of dementia Event, n Rate (95%CI), per 100 person Age group (years) * 44 13/7, [ ] /13, [ ] 65 years 383/8, [ ] Sex Female 269/16, [ ] Male 192/12, [ ] Insurance amount (NT$) 40,000 21/3, [ ] 20,000-39,999 50/5, [ ] < NT$20, /12, [ ] Region North 178/12, [ ] Center 130/7, [ ] South 137/8, [ ] East 11/ [ ] Urbanicity 1 (most urbanized) 109/9, [ ] 2 125/8, [ ] 3 70/4, (least urbanized) [ ] 104/4, [ ] With Depression (n=1,403) 2.05 [ ] [ ] 1.02 [ ] 4.05 [ ] 5.64 [ ] 1.10 [ ] 1.03 [ ] 2.02 [ ] 0.75 [ ] 1.02 [ ] 1.30 [ ] Crude OR [95%CI] Without Depression (n=27,692) 2.96 [ ] [ ] 0.96 [ ] 1.42 [ ] 3.09 [ ] 1.35 [ ] 1.21 [ ] 1.11 [ ] 1.34 [ ] 1.40 [ ] 2.15 [ ] Total (n=29,095) 2.92 [ ] [ ] 0.94 [ ] 1.54 [ ] 3.27 [ ] 1.32 [ ] 1.20 [ ] 1.20 [ ] 1.25 [ ] 1.33 [ ] 2.02 [ ] With Depression (n=1,403) 1.78 [ ] [ ] 0.96 [ ] 3.75 [ ] 5.27 [ ] 1.21 [ ] 1.10 [ ] 1.74 [ ] 0.72 [ ] 1.12 [ ] 1.31 [ ] Adjusted OR [95%CI] Without Depression (n=27,692) 2.70 [ ] [ ] 0.93 [ ] 1.42 [ ] 2.85 [ ] 1.33 [ ] 1.15 [ ] 1.04 [ ] 1.33 [ ] 1.42 [ ] 1.96 [ ] Total (n=29,095) 2.64 [ ] *** [ ] 0.91 [ ] 1.54 [ ] 3.00 *** [ ] 1.31 [ ] 1.14 [ ] 1.13 [ ] 1.25 [ ] 1.36 [-1.84] 1.86 *** [ ] 12
12 With Depression (n=1,403) Risk factors Stroke [Without] [With] 2.18 [ ] Diabetes Mellitus [Without] [With] 2.20 [ ] Hypertension [Without] [With] 2.24 [ ] Hyperlipidemia [Without] [With] 1.78 [ ] Antidepressants Usage [Without] [With] 2.07 *** [ ] *Multivariate analysis adjusted for stroke, diabetes mellitus, hypertension and hyperlipidemia. Adjusted OR [95%CI] Without Depression (n=27,692) 2.60 [ ] 1.87 [ ] 2.82 [ ] 1.25 [ ] 2.58 *** [ ] Total (n=29,095) 2.70 [ ] 1.90 [ ] 2.75 [ ] 1.32 [ ] 2.66 *** ] 13
13 DISEASE-FREE DURATIONS 14
14 Disease-Free Probability Figure 1 Kaplan-Meier failure curve of study and control group patients who developed dementia Nonuser controls: 266/23,276 (Rate: 1.14%) 0.95 Antidepressant user cases: 195/5,819 (Rate: 3.35%) Log Rank test: p< Time (days) The median follow-duration for cases and nonuser were 6.76 & 8.92 years. 15
15 13 ANTIDEPRESSANTS TCAs and TeCAs SSRIs MAOIs SARIs SNRIs 16
16 Table 3 Risk of dementia as use of antidepressants (Reference=Control) Exposed to Study and control (n=29,095) Crude OR [95%CI] Adjusted OR [95%CI] n (%) Control 23,276 Selective serotonin reuptake inhibitors (SSRIs) Fluoxetine (Prozac) 825 (14.18%) 0.95 [ ] 0.97 [ ] Citalopram (Celexa) 299 (5.14%) 2.99 [ ] 2.85 [ ] Escitalopram (Lexapro, Cipralex) 101 (1.74%) 2.65 [ ] 2.27 [ ] Fluvoxamine (Luvox) 179 (3.08%) 3.00 [ ] 2.81 [ ] Sertraline (Zoloft, Lustral) 538 (9.25%) 2.65 [ ] 2.53 [ ] Paroxetine (Paxil, Seroxat) 429 (7.37%) 3.79 [ ] 3.33 [ ] Selective norepinephrine reuptake inhibitors (SNRIs) Venlafaxine (Effexor) 384 (6.60%) 3.03 [ ] 2.85 [ ] Tricyclic antidepressants (TCAs) Amitriptyline (Elavil, Endep) 333 (5.72%) 3.80 [ ] 3.14 [ ] Imipramine (Tofranil) 1,065 (18.30%) 3.03 [ ] 2.14 [ ] Doxepin (Adapin, Sinequan) 185 (3.18%) 2.40 [ ] 2.12 [ ] Tetracyclic antidepressants (TeCAs) Mirtazapine (Remeron) 223 (3.83%) 4.06 [ ] 3.66 [ ] Monoamine oxidase inhibitors (MAOIs) Moclobemide (Aurorix, Manerix) 155 (2.66%) 3.48 [ ] 2.95 [ ] Serotonin antagonist and reuptake inhibitors (SARIs) *Multivariate Trazodone (Desyrel) analysis adjusted for stroke, depression, 1,103 diabetes mellitus, (18.96%) hypertension, 4.02 [ ] and hyperlipidemia [ ] 17
17 17
18 DOSAGE- DEPENDENT 19
19 Table 4. Logistic regressions on the risk of dementia associated with antidepressants by cumulative DDDs Event, n Antidepressants cddds Rate (95%CI), per 100 person With Depression (n=1,403) Crude OR [95%CI] Without Depression (n=27,692) Total (n=29,095) With Depression (n=1,403) Adjusted OR [95%CI] Without Depression (n=27,692) Total (n=29,095) No use 266/23, [ ] <90 137/4, [ ] /1, [ ] >180 28/ [ ] 1.54 [ ] 1.59 [ ] 2.37 [ ] 2.94 [ ] 2.41 [ ] 3.50 [ ] 2.95 [ ] 2.62 [ ] 3.92 [ ] 1.76 [ ] 2.22 [ ] 3.16 *** [ ] 2.54 *** [ ] 2.42 *** [ ] 3.15 *** [ ] 2.44 [ ] *** 2.43 [ ] *** 3.29 [ ] *** cddds, cumulative defined daily doses; OR, odds ratio; CI, confidence interval. *Adjusted by stroke, depression, diabetes mellitus, hypertension, and hyperlipidemia. 20
20 Dementia Risk Odds for dementia of 13 antidepressants were significantly different CONCLUSION Antidepressants medications are associated with 3 Controls dementia in 2.58 a manner 2.66 independent of depression. Cases Both depression & non-depression antidepressant user cases had higher incidence of dementia With Depression (n=1,403) Without Depression (n=27,692) Total (n=29,095) With Depression (n=1,403) Antidepressants cddds No use Adjusted OR [95%I] Without Depression (n=27,692) Total (n=29,095) < Dose-dependent [ ] [ ] risk of [ ] dementia with antidepressants use [ ] [ ] [ ] > [ ] 3.15 [ ] 3.29 [ ] 21
21 Discussion 1 Dementia may be an Iatrogenic result of taking antidepressant medication, besides of pathogenic consequence of depression. 22
22 Discussion 2 Fluoxetine is least dementia-associated antidepressant. Fluoxetine can rescue the effect after exposure to inescapable shock Fluoxetine can enhance hippocampal neurogenesis in long term depression Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. Sep 2003;28(9): Chen H, Pandey GN, Dwivedi Y. Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport. Jun ;17(9):
23 Cell Viability (Compared to Control) *** AKA *** *** *** AKA Antidepressant-induced cell * * *** * death of astrocyte AKA-3 AKA *** ** * *** *** AKA-5 AKA-6 AKA (um) (um) * ** ** AKA-9 *** *** AKA-10 * *** ** ** ** * * * AKA-8 AKA (um) 24
24 Counts AKA-1-induced ROS generation of astrocyte Control H 2 O 2 (AKA-1) 2.5mM DCF fluorescence intensity (% of control) C H 2 O 2 AKA-1 (um) Sertraline (mm) (AKA-1) 5mM AKA-1 combined with amyloid beta Increased cytotoxicity in astrocyte (AKA-1) 7.5mM (AKA-1) 10mM Fluorescence intensity (DCF) 25
25 CONCLUSION Antidepressants medications are associated with dementia in a manner independent of depression. 26
26 The End 27
27 Flowchart of subjects selection National Health Insurance Research Database (NHIRD) In Random sample of NHI insured in (N=1,000,000) Cases (n=8553) were selected with taking any of 13 antidepressants, complied with two conditions: (1) interval between two continuous antidepressant -prescribed visits should be less than 30 days; (2) the first and last antidepressant-prescribed visits should more than 30 days apart. Controls (n=51,755) were matched to cases according to the age, sex, and index date, complied with one condition: (1) No any history of taking antidepressants Exclude (1) Patients who had been taking more than one type of antidepressant in (n=853) (2) Diagnosed dementia before taking antidepressant, pseudo-prescribed and (n=3,043) (3) Aged over 80 in 2015 (n=66,608) (4) Patients with undetermined gender (n=12,633) Study group Antidepressant long term users (n=5819) Control group Non antidepressant users (n=23,276) Follow-up until
28 Table 1. Comparison of Demographic Characteristics and Risk Factors Between Cases and Controls. Study (N=5819) Control (N=23,276) N (%) N (%) P Value Age, mean (SD) a (14.97) (14.99).942 Sex (male) a 2508 (43.10%) 10,032 (43.10%) 0 Insurance amount (NT$) b,c < , (14.14%) 2955 (17.18%) 20,000-39, (21.64%) 4580 (26.62%) <20, (64.22%) 9670 (56.20%) Region b,c.916 Northern 2565 (44.31%) 10,312 (44.51%) Central 1414 (24.43%) 5740 (24.77%) Southern 1639 (28.31%) 6622 (28.58%) Eastern 171 (2.95%) 495 (2.14%) Urbanicity b,c (most urbanized) 1744 (33.23%) 7439 (35.12%) (33.31%) 6672 (31.50%) (15.68%) 3621 (17.09%) 4 (least urbanized) 933 (17.78%) 3450 (16.29%) Risk factors b Stroke 357 (6.14%) 610 (2.62%) <.001 Depression 969 (16.65%) 434 (1.86%) <.001 Diabetes Mellitus 721 (12.39%) 2103 (9.04%) <.001 Hypertension 1128 (19.38%) 3903 (16.77%) <.001 Hyperlipidemia 775 (13.32%) 2514 (10.80%).040 Insomnia 1145 (19.68%) 1876 (8.06%) <.001 Anxiety 1378 (23.68%) 2005 (8.61%) <.001 CCI Score b < (89.21%) 21,666 (93.08%) (6.22%) 1023 (4.40%) (4.57%) 587 (2.52%) Antidepressant cddd, mean (SD) (181.90) Antidepressant cddd < (71.37%) (17.53%) > (11.10%) a T test. b Chi-square test. c Subjects for all levels do not sum up to original cases due to missing values. 29
29 Table 2: Risk Factors Examination for Dementia using Cox Proportional Hazards Regression Model. Event, n Rate (95% CI), per 100 persons Univariate HR [95% CI] Multivariate HR [95% CI] P Value Age (years) 1.13 [ ] 1.12 [ ]** <.001 Sex.806 Female 210/16, [ ] Male 146/12, [ ] 0.93 [ ] 0.97 [ ] Insurance amount (NT$) < ,000 17/ [ ] 20,000-39,999 38/ [ ] 1.45 [ ] 1.41 [ ] <20, /12, [ ] 3.09 [ ] 2.63 [ ]** Region.515 Northern 138/12, [ ] Central 100/ [ ] 1.30 [ ] 1.22 [ ] Southern 105/ [ ] 1.18 [ ] 1.12 [ ] Eastern 9/ [ ] 1.28 [ ] 1.15 [ ] Urbanicity (most urbanized) 81/ [ ] 2 103/ [-1.48] 1.39 [ ] 1.37 [ ]* 3 55/ [ ] 1.41 [-1.98] 1.44 [ ]* 4 (least urbanized) 73/ [ ] 1.90 [ ] 1.65 [ ]** CCI Score /28, [ ] 2 12/ [ ] 3.78 [ ] 1.51 [ ]* 3 4/ [ ] 5.03 [ ] 1.53 [ ]* Depression.011 [Without] 316/27, [ ] [With] 40/ [ ] 2.85 [ ] 1.59 [ ]* Antidepressant Usage <.001 [Without] 200/23, [ ] [With] 156/ [ ] 5.03 [ ] 3.89 [ ]** Depression*Antidepressant.193 Antidepressant effect (Depression=N) 5.08 [ ] 4.05 [ ] Antidepressant effect (Depression=Y) 2.27 [ ] 2.42 [ ] *:p<0.05, **: p<
30 Table 3: Risk of Dementia with the Use of Antidepressants from Different Classes (Reference=Control). Exposed to Study (N=5819) N (%) Univariate HR [95% CI] Multivariate HR [95% CI] Selective serotonin reuptake inhibitors (SSRIs) 2371 (40.75%) 4.10 [ ] 3.66 [ ]** Selective norepinephrine reuptake inhibitors (SNRI) 384 (6.60%) 5.35 [ ] 4.73 [ ]** Tricyclic antidepressants (TCAs) 1583 (27.20%) 4.64 [ ] 3.26 [ ]** Tetracyclic antidepressants (TeCA) 223 (4.00%) 8.29 [ ] 6.62 [ ]** Monoamine oxidase inhibitors (MAOI) 155 (2.66%) 6.72 [ ] 4.94 [ ]** Serotonin antagonist and reuptake inhibitors (SARI) 1103 (18.96%) 6.56 [ ] 4.48 [ ]** *:p<0.05, **: p<0.01. SSRIs include Fluoxetine, Citalopram, Escitalopram, Fluvoxamine, Sertraline, Paroxetine; SNRI includes Venlafaxine; TCAs include Amitriptyline, Imipramine, Doxepin; TeCA includes Mirtazapine; MAOI includes Moclobemide; SARI includes Trazodone. 31
31 Table 4: Examination of the Risk Factors of Dementia in terms of the Antidepressant cddd and its Side Effects using Cox Proportional Hazards Regression. Event, n Rate (95% CI), per 100 persons Univariate HR [95% CI] Multivariate HR [95% CI] P for trend Antidepressant cddd <.001 No use 200/23, [ ] <90 108/ [ ] 4.89 [ ] 3.74 [ ]** / [ ] 4.45 [ ] 3.73 [ ]** >180 24/ [ ] 6.69 [ ] 5.22 [ ]** Side effects of antidepressant medications Sedation a / [ ] 1+ 30/ [ ] 1.64 [-2.71] 1.56 [ ] 3+ 31/ [ ] 1.34 [ ] 1.04 [ ] 4+ 57/ [ ] 1.86 [ ] 1.47 [ ] Side effects of antidepressant medications Anticholinergic a / [ ] 1+ 25/ [ ] 1.57 [ ] 1.60 [ ]* 3+ 31/ [ ] 0.99 [ ] 0.84 [ ] 4+ 9/ [ ] 1.05 [ ] 0.93 [ ] *:p<0.05, **: p<0.01. a Scale: 0 = none; 1+ = slight; 2+ = low; 3+ = moderate; 4+ = high. About the potency of sedative property of antidepressants, 0 for Fluoxetine, Citalopram, Escitalopram, and Sertraline; 1+ for Fluvoxamine, Paroxetine, and Venlafaxine; 3+ for Imipramine and Doxepin; 4+ for Amitriptyline, Mirtazapine, and Trazodone. About the potency of anticholinergic property of antidepressants, 0 for Fluoxetine, Citalopram, Escitalopram, Sertraline, Fluvoxamine, Trazodone, and Venlafaxine; 1+ for Paroxetine and Mirtazapine; 2+ for Imipramine and Doxepin; 4+ for Amitriptyline. 32
32 Table 5: Assessment of Risk Factors for Dementia using Cox Proportional Hazards Regression Model. Risk Factor Univariate HR [95% CI] Multivariate HR [95% CI] Stroke 6.22 [ ] 2.55 [ ]** Diabetes Mellitus 3.51 [ ] 1.58 [ ]** Hypertension 4.06 [ ] 2.27 [ ]** Hyperlipidemia 2.85 [ ] 1.27 [ ] Depression 2.85 [ ] 1.59 [ ]* Insomnia 2.94 [ ] 1.64 [ ]** Anxiety 2.69 [ ] 1.49 [ ]** CCI Score (2 vs. 1) 3.78 [ ] 1.51 [ ]* CCI Score ( 3 vs. 1) 5.03 [ ] 1.53 [ ]* *:p<0.05, **: p<
33 Table 6: Subgroup Analysis of Cox Proportional Hazard Regressions of Antidepressant Associated with the Incidence of Dementia. Subgroup Univariate HR [95% CI] Multivariate HR [95% CI] Age group [ ] 2.47 [ ] [ ] 8.34 [ ]** [ ] 3.84 [ ]** Gender [Female] 4.80 [ ] 3.59 [ ]** [Male] 5.37 [ ] 4.45 [ ]** Stroke [Without] 4.81 [ ] 4.08 [ ]** [With] 3.09 [ ] 2.90 [ ]** Diabetes Mellitus [Without] 4.73 [ ] 3.90 [ ]** [With] 4.71 [ ] 3.91 [ ]** Hypertension [Without] 4.97 [ ] 4.09 [ ]** [With] 4.52 [ ] 3.65 [ ]** Hyperlipidemia [Without] 4.94 [ ] 4.04 [ ]** [With] 4.54 [ ] 3.51 [ ]** Depression [Without] 5.12 [ ] 4.07 [ ]** [With] 2.19 [ ] 2.54 [ ]* Insomnia [Without] 4.45 [ ] 3.55 [ ]** [With] 4.50 [ ] 4.96 [ ]** Anxiety [Without] 4.70 [ ] 3.92 [ ]** [With] 3.76 [ ] 3.67 [ ]** CCI score [ ] 4.07 [ ]** [ ] 2.99 [ ]** *:p<0.05, **: p< [ ] 3.79 [ ]** 34
34 Kaplan-Meier estimates of study and control group patients who developed dementia 35
35 Fig 3. Forest Plot of Factors Associated with the Incidence of Dementia. 36
36 S1 Fig. The plot of log(-log(survival function)) versus log of survival time. 37
37 S2 Fig. Kaplan-Meier Estimates of Study and Control Group Patients Who Developed Dementia after 5 years of index date. 38
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationERIC J. NESTLER, MD, PhD
ERIC J. NESTLER, MD, PhD NASH FAMILY PROFESSOR OF NEUROSCIENCE CHAIR, DEPARTMENT OF NEUROSCIENCE DIRECTOR, FRIEDMAN BRAIN INSTITUTE MOUNT SINAI SCHOOL OF MEDICINE Please do not use or distribute without
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationAntidepressants. BMF 83 - Antidepressants
Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals in the brain, namely serotonin and
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More information90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationA Retrospective Claims Analysis of Medication Adherence and. Persistence Among Patients Taking Antidepressants
A Retrospective Claims Analysis of Medication Adherence and Persistence Among Patients Taking Antidepressants for the Treatment of Major Depressive Disorder (MDD) Katelyn R. Keyloun A thesis submitted
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationDuragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist
Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationMajor Depressive Disorder
Major Depressive Disorder HEDIS Measures And Clinical Practice Guidelines Jennifer Highley, PMHNP-BC Behavioral Health West Point Healthcare Effectiveness Data and Information Set (HEDIS) Performance measures
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationMORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More informationParoxetine and the elderly
Paroxetine and the elderly The Borg System is 100 % Paroxetine and the elderly Doxepin >6mg/day (Silenor). Imipramine (Tofranil). Nortriptyline (Pamelor). Paroxetine (Paxil). Trimipramine (Surmontil).
More informationSupplementary figures and tables. Figure A: Study schematic
Supplementary figures and tables Figure A: Study schematic Figure B: Percent of patients with a normal (green), borderline (beige), abnormal (brown), or high (red) electrocardiogram 14-90 days after prescription
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationParoxetine and the elderly
Paroxetine and the elderly The Borg System is 100 % Paroxetine and the elderly Paroxetine, a antidepressant, is considered to have fewer side-effects than a typical tricyclic antidepressant. As the elderly
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationClinical Policy: Levomilnacipran (Fetzima) Reference Number: HIM.PA.125 Effective Date: Last Review Date: 11.18
Clinical Policy: (Fetzima) Reference Number: HIM.PA.125 Effective Date: 12.01.17 Last Review Date: 11.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationLinda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010
Pharmacologic Treatment of Depression Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010 1 Disclosure I have no
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationPrimary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017
John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
More informationXartemis XR (oxycodone / acetaminophen extended release)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Xartemis XR is a combination of oxycodone and acetaminophen in a dosage formulation to deliver both immediate pain relief, in less than an hour, and extended-release
More informationManagement of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*
Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationAnti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of.
30-3-2007 Anti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of. 30-3-2018 C. Psychiatric drugs: controlled trial demonstrated
More informationDepression Pharmacology. PHPP 517 (IT-III) Fall 2011
Depression Pharmacology PHPP 517 (IT-III) Fall 2011 Depression Symptoms of Depression Emotional symptoms Physical symptoms Cognitive symptoms Psychomotor symptoms Depression Pharmacology Loss of brain
More informationBefore you try another medication, try asking your DNA
Before you try another medication, try asking your DNA It s not you, it s your genetics If you re having trouble finding a medication that works for you, don t give up hope. Here s the thing we all respond
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationRuby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018
Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Objectives Describe pharmacology of commonly prescribed drugs for stimulants and hypnotics Brief review of common drugs that affect sleep
More informationAntidepressants. NEPHAR 305 Pharmaceutical Chemistry I. Assist.Prof.Dr. Banu Keşanlı
Antidepressants EPHAR 305 Pharmaceutical Chemistry I Assist.Prof.Dr. Banu Keşanlı 1 Antidepressants What is depression? Depression is not a disease per se, but a clinical disorder that is manifested by
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationBELBUCA (buprenorphine buccal film)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Belbuca is indicated for the management of chronic pain severe enough to require daily, aroundthe-clock, long-acting opioid treatment for which alternative
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationMedications Guide: Public Speaking And Social Anxiety
AnxietyHub.org Dr. Cheryl Mathews Medications Guide: Public Speaking And Social Anxiety Copyright 2016 AnxietyHub Medications Specifically for Public Speaking and Social Anxiety This is not intended to
More informationNortriptyline vs amitriptyline in elderly
Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are
More informationChange Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness
Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More informationAverage dose zoloft for ocd and anxiety
Average dose zoloft for ocd and anxiety Gogamz Menu DESCRIPTION. Selective serotonin reuptake inhibitor (SSRI). Approved for depression, OCD, panic disorder, PTSD, premenstrual-dysphoric disorder (PMDD),
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationOverview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials
SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationMental Health Nursing: Mood Disorders. By Mary B. Knutson, RN, MS, FCP
Mental Health Nursing: Mood Disorders By Mary B. Knutson, RN, MS, FCP A Definition of Mood Prolonged emotional state that influences the person s whole personality and life functioning Adaptive Functions
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Methadone hydrochloride is a long-acting opioid agonist at mu-opioid receptors that is used to manage pain that requires long-term, daily opioid treatment
More informationTREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD
TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high
More informationTreating Depression in Adults
Treating Depression in Adults By Deborah Christensen, Ph.D., M.S.C.P. Depressive Disorders represent a broad and heterogeneous group of commonly diagnosed psychological disorders. The DSM adequately describes
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationSUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Managing Depression in Older Adults Developed March 1, 2003 Revised September 21,
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationFROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY
13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationReliable and reproducible effect size estimates at scale
Reliable and reproducible effect size estimates at scale Marc A. Suchard, M.D., Ph.D. Departments of Biomathematics and Human Genetics David Geffen School of Medicine at UCLA, and Department of Biostatistics
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationEducational Objectives: Outline. Relevant Disclosures. Managing Depression in Primary Care Lake Tahoe, August 2011
Managing Depression in Primary Care Lake Tahoe, August 2011 Descartes Li, M.D. Clinical Professor University of California, San Francisco descartes.li@ucsf.edu Educational Objectives: By the end of the
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Tramadol is a centrally acting synthetic opioid analgesic used to treat moderate to moderately severe chronic pain in adults. Along from analgesia, tramadol
More informationDepression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.
Depression Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with depressed mood can feel sad, anxious,
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationYour Kailos Test. Sample ID: CL-4194-DM. Jane Doe DOB: Hello Jane,
1 Jane Doe DOB: 1985-01-05 Sample ID: CL-4194-DM Hello Jane, Thank you for ordering your Kailos test for antidepressants. Kailos Genetics is committed to making gene-based healthcare available to YOU.
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationAn Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population
An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population A Population-Based Case-Control Study Hsin-I Shih, Che-Chen Lin, Yi-Fang Tu, Chia-Ming Chang,
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationClassification of psychotropic drugs
Dept. of Pharmacology, Faculty of Medicine, Masaryk University Antidepressants Notes for Pharmacology II Practicals This study material is exclusively for students of general medicine and dentistry in
More informationPsycho-pharmacologic Therapy. Objectives
Psycho-pharmacologic Therapy for Functional Bowel Disorders John J. Hutchings, M.D. Assistant Professor of Medicine and Psychiatry Louisiana i State t University it School of Medicine i Department of Medicine
More informationTreatment of Major Depressive Disorder
Treatment of Major Depressive Disorder Sarah Mullowney, MD PGY3 Psychiatry Resident, University of Utah Paula Gibbs, MD Medical Director of 5 West at UUMC Clerkship Director MS III Psychiatric Rotation
More informationPHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS
PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS Yogesh Dwivedi, Ph.D. Assistant Professor of Psychiatry and Pharmacology Psychiatric Institute Department of Psychiatry
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background hydromorphone (Exalgo, Dilaudid) and oxymorphone (Opana and Opana ER) are Schedule II narcotics prescribed to treat moderate to severe pain. Morphine produces
More informationReviews/Evaluations. Guidelines for Cost-Effective Use of Antidepressants. Current Utilization (January 1, 2002 through December 31, 2002)
Reviews/Evaluations Guidelines for Cost-Effective Use of Antidepressants Current Utilization (January 1, 2002 through December 31, 2002) OHP spent $54 million on antidepressant medications (Class 11) Drug
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trintellix) Reference Number: CP.PMN.65 Effective Date: 05.01.15 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy
More informationClinical Policy: Vilazodone (Viibryd) Reference Number: CP.PMN.145 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Viibryd) Reference Number: CP.PMN.145 Effective Date: 08.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationButrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butrans Page: 1 of 9 Last Review Date: September 15, 2017 Butrans (buprenorphine patch) Description
More informationMajor Depressive Disorder: Diagnosis, Treatment & Impact on Rural Communities
Page 1 Major Depressive Disorder: Diagnosis, Treatment & Impact on Rural Communities Elizabeth Montagnese, M.D. Adult, Child and Adolescent Psychiatrist This program has been supported by an educational
More information8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation
Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary
More informationMajor depressive disorder (MDD) is the most prevalent. Clinical Guidelines
Clinical Guidelines Annals of Internal Medicine Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Gerald Gartlehner, MD, MPH;
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Meperidine Page: 1 of 7 Last Review Date: September 15, 2017 Meperidine Description Demerol (meperidine
More informationProfessional Practice Minutes September 7 th, 2016
Professional Practice Minutes September 7 th, 2016 1. Lung Cancer Screening : Fast Facts Number 1 killer of both men and women in the US (The Global Burden of Cancer 2013) More people die from lung cancer
More informationProfessor David Castle. Ms. Nga Tran. St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065
ARABIIC Professor David Castle Ms. Nga Tran St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065 (03) 9288 4147 (03) 9288 4751 Psychiatric Medication Information / Arabic 1 Psychiatric
More informationUnderstanding Alzheimer s Disease
Understanding Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disorder that slowly impacts memory, thinking, skills and, eventually, the ability to carry out the simplest
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 8 Last Review Date: September 15, 2017 Embeda Description Embeda (morphine
More information